GLP-1 Support Supplements: Formulation and Ingredient Innovations

GLP-1 support supplements, also called GLP-1 companion nutrition, are dietary supplements and functional foods formulated for people using glucagon-like peptide-1 (GLP-1) receptor agonist medications such as semaglutide and tirzepatide, or seeking similar appetite and metabolic support. They are designed to offset predictable consequences of large, drug-driven appetite suppression: loss of lean muscle mass, below-target intake of protein, fiber, and micronutrients, and gastrointestinal side effects.

For product developers, the core formulation levers are consistent:

• Muscle preservation: protein (whey for rapid delivery, casein for sustained release), essential amino acids, creatine, and HMB.
• Satiety and glycemic support: soluble, viscous, and fermentable fibers such as glucomannan, psyllium, inulin, beta-glucan, and resistant maltodextrin.
• Nutrient adequacy and tolerability: B-vitamins, vitamin D, iron, magnesium, potassium, electrolytes, and GI-comfort aids.

The central constraint is delivering meaningful doses inside small, nausea-sensitive serving sizes, which shapes the choice between stick-packs, ready-to-mix shakes, effervescents, gummies, and capsules.

Importantly, no trial has yet tested these supplements taken alongside a GLP-1 drug, so recommendations are extrapolated. This article covers formulation and dosage form first, then the trends Vitafoods Europe 2026 surfaced.

Table of Contents

• What Are GLP-1 Support Supplements
• Muscle Preservation: Protein, Amino Acids, Creatine, and HMB
• Fiber and Satiety: Viscous Fibers and the Endogenous GLP-1 Route
• Micronutrients, Electrolytes, and GI Tolerability
• Matching Dosage Form to a Small, Nausea-Sensitive Serving
• The Core Formulation Challenges
• GLP-1 Companion Nutrition at Vitafoods Europe 2026
• Muscle and Energy: HTBA Leanara and Protein-Led Launches
• Satiety and Metabolic Positioning: Fibers and Collagen Peptides
• Format Innovation: Stick-Packs, Sachets, and Melt-in-Mouth
• Regulatory and Claims Guardrails
• Frequently Asked Questions
• Key Takeaways
• Sources

What Are GLP-1 Support Supplements

GLP-1 support supplements are products formulated to address the nutritional gaps and side effects associated with GLP-1 receptor agonist (GLP-1RA) therapy, rather than to replicate the drug. The clinical rationale is specific. GLP-1RA drugs reduce total caloric intake by roughly 16 to 39 percent, and while most of the resulting weight loss is fat, a smaller but consistent share is lean tissue, commonly cited in the range of about 25 to 40 percent of weight lost, with some analyses citing higher figures where loss is rapid and unmanaged [1, 2]. That combination of steep intake reduction and lean-mass risk defines what a companion formulation has to do.

The category spans several intents: preserving muscle, sustaining satiety without the drug, easing nausea and constipation, and preventing micronutrient shortfalls. A useful orientation to the evidence base is this narrative review of supplement considerations during GLP-1 receptor agonist treatment, which maps the ingredient classes to the specific deficits they target. The key discipline for developers is honesty about evidence: the supportive-care model is extrapolated from obesity, weight-loss, and bariatric research, because no study has yet tested a supplement and a GLP-1RA together [2].

See and download our infographic on GLP-1 Support Supplements:

Muscle Preservation: Protein, Amino Acids, Creatine, and HMB

Protein is the primary muscle-preservation lever, and it is the ingredient class most GLP-1RA users under-consume. Clinical guidance for preserving lean mass during weight loss points to roughly 1.2 to 2.0 g of protein per kg of adjusted body weight per day, yet compliance data suggest most users fall short, with one small cohort finding only around 43 percent reaching 1.2 g/kg and far fewer reaching higher targets [1, 3]. Because appetite is suppressed, the practical answer is protein density per serving rather than larger meals: whey delivers a rapid rise in circulating amino acids (peak around 90 minutes), while casein and calcium caseinate release more slowly over several hours and support sustained satiety [1]. Essential amino acid (EAA) and leucine blends offer a low-volume way to reach the leucine threshold that triggers muscle protein synthesis.

Creatine monohydrate is the best-supported adjunct. At 5 g per day combined with resistance training, it is associated with an increase in lean body mass of roughly 1.1 kg on average, and about 1.32 kg in older adults, with a strong safety record, though the average masks a meaningful difference between subgroups [1]. HMB (beta-hydroxy-beta-methylbutyrate) at about 3 g per day is a second adjunct: it is understood to activate the mTOR (mechanistic target of rapamycin) pathway and inhibit muscle protein breakdown, and a meta-analysis in older adults reported a modest standardized benefit, but the wider evidence is mixed and generally null in trained individuals capable of structured resistance exercise [1]. For formulators, this hierarchy matters: protein and creatine carry the strongest support, while EAAs, leucine, and HMB are reasonable adjuncts positioned on indirect evidence. The same evidence on complete amino acid profiles that governs plant protein blends applies here, since protein quality, not just quantity, drives the muscle-preservation outcome.

Fiber and Satiety: Viscous Fibers and the Endogenous GLP-1 Route

Soluble and viscous fibers are the satiety workhorses of the category, and a subset can nudge the same gut-hormone pathway the drugs target. Glucomannan, psyllium, inulin, beta-glucan, and resistant maltodextrin form viscous gels that slow gastric emptying and blunt postprandial glucose. Fermentable fibers go a step further: gut bacteria ferment them into short-chain fatty acids that act on the free fatty acid receptors FFAR2 and FFAR3 on intestinal L-cells, stimulating the body’s own secretion of GLP-1 and peptide YY (PYY) [4]. In one randomized study, a resistant maltodextrin (Fibersol) significantly raised GLP-1 and PYY at a 10 g per meal dose but not at 5 g, which illustrates how dose-dependent this endogenous effect is [4]. This mechanism is why slow-release carbohydrates and prebiotic fibers are increasingly positioned to raise endogenous GLP-1 and PYY as a non-drug route to appetite regulation.

The honest framing is that fiber’s standalone effect on weight is small relative to the drugs. Viscous fibers add on the order of 0.3 to 0.8 kg of weight loss versus control, whereas semaglutide and tirzepatide produce placebo-subtracted losses of roughly 10 to 20 kg or more [4, 5]. A double-blind trial of a glucomannan, inulin, and psyllium blend reported a 4.9 percent treatment difference over 180 days, but with a 74.6 percent rate of (mostly mild and transient) gastrointestinal adverse events versus none on placebo, which underlines that GI tolerability, driven by viscosity and fermentation, is the central fiber formulation challenge [5]. On the regulatory side, the European Food Safety Authority (EFSA) has authorised a claim that glucomannan contributes to weight loss in the context of an energy-restricted diet at 3 g per day taken in three 1 g doses with water, subject to a mandatory choking warning for anyone with swallowing difficulty or inadequate fluid intake, and an authorised oat beta-glucan claim for maintenance of normal blood cholesterol at 3 g per day [6]. Those conditions are formulation constraints in themselves, since the dose and the fluid warning shape both the format and the label.

Micronutrients, Electrolytes, and GI Tolerability

Micronutrient support addresses the arithmetic of eating far less food. Sustained caloric restriction on GLP-1RA therapy is associated with intake below the Dietary Reference Intake (DRI) for calcium, iron, magnesium, potassium, and vitamins A, C, D, and E, alongside an average fiber intake near 14.5 g per day against a 25 to 38 g recommendation [1, 3]. One large retrospective analysis found more than 22 percent of users developed at least one nutritional deficiency within 12 months, with vitamin D the most common, though such figures come from observational and industry-funded data and should be read as directional rather than definitive [1]. Risk-based support therefore centers on vitamin D, B12, iron, and a broad-spectrum multivitamin.

Fluid and mineral balance is a parallel concern. Reduced food and fluid intake, sometimes compounded by vomiting or diarrhea, can leave users short on sodium, potassium, and magnesium, which is why electrolytes feature in many companion formats. Digestive tolerability rounds out the picture: probiotics and postbiotics are positioned to stabilise the microbiota, while ginger and similar botanicals are used for nausea, and adequate fiber and fluid help manage the constipation that commonly accompanies slowed gastric motility. Each of these is a structure-function or comfort positioning, not a treatment claim.

Matching Dosage Form to a Small, Nausea-Sensitive Serving

Dosage form selection is unusually decisive in this category because the target user eats little and tolerates strong flavors poorly. High-dose actives such as protein, fiber, and creatine need volume, which points to powders and drinks; low-dose actives such as vitamins, B12, and electrolytes fit compact formats. The result is a portfolio logic rather than a single hero format.

Table 1. Indicative fit between dosage form and GLP-1 companion actives. Capacities vary with formulation and equipment; treat as directional.

The reference-table logic below summarizes the actives and their working doses, so a developer can size a serving against what the format can carry.

Table 2. Companion actives, working doses, and evidence notes.

The Core Formulation Challenges

The defining challenge is nutrient density inside a serving a GLP-1RA user can actually finish. Appetite suppression shrinks tolerable volume, so a companion product often has to deliver protein, fiber, and micronutrients in a fraction of a normal serving, which pushes formulators toward concentrated proteins, low-volume EAA blends, and stick-pack dosing rather than large shakes.

Three technical tensions follow from that. First, protein-fiber systems fight each other on viscosity and stability: viscous fibers that drive satiety also thicken a mix and can make a high-protein powder gel or resist dispersion, so solubility engineering and stabilizer selection become central. Second, taste-masking carries unusual weight because drug-induced nausea can create flavor aversions, meaning off-notes are penalised harder than in a general-population product. Third, satiety and dosing timing matter, since viscous fibers work best taken with water before a meal, which turns the regimen itself into a compliance variable alongside pill and sachet burden.

Underlying all of it is the evidence gap. Because no trial has directly tested any of these ingredients alongside semaglutide or tirzepatide, claims must stay within substantiated structure-function language and avoid implying the product treats obesity or replaces the medication [2].

GLP-1 Companion Nutrition at Vitafoods Europe 2026

Vitafoods Europe 2026, held May 5 to 7 in Barcelona, made GLP-1 companion nutrition one of its defining themes, with dedicated conference sessions and a wave of ingredient launches aimed squarely at the muscle, satiety, and nutrient-adequacy problems above [14, 15]. The floor coverage and ingredient highlights are captured in the Vitafoods Europe 2026 recap. What the show demonstrated is that the category has moved from concept to a commercially defined set of ingredient and format solutions, organised around the same physiology this article opened with.

Muscle and Energy: HTBA Leanara and Protein-Led Launches

Muscle preservation and energy were the headline positioning at the show. HTBA (HealthTech Bio Actives) launched Leanara, a dual-action ingredient pairing patented citrus bioflavonoids with a bioavailable, active form of vitamin B12, positioned to help preserve or increase lean muscle and support energy during GLP-1 weight loss, and presented in a mango-flavoured stick-pack that reflects the small-serving format logic of the category [8, 9]. Protein suppliers reinforced the same theme: Arla Foods Ingredients showed high-protein, nutrient-dense application concepts formulated for reduced-intake users [12], and FrieslandCampina Ingredients positioned whey for rapid amino-acid delivery and casein for sustained release and satiety, aligning supplier messaging with the roughly 1.2 to 1.6 g/kg practitioner target for muscle maintenance [11]. Gnosis by Lesaffre presented named muscle-support actives including creatine and HMB for the GLP-1 context [10]. Across these, the common message was that muscle-first formulation, not appetite suppression, is where companion products add value.

Satiety and Metabolic Positioning: Fibers and Collagen Peptides

Satiety and metabolic support formed the second cluster. Soluble fibers, including resistant maltodextrin (Fibersol), were positioned for satiety, postprandial glucose control, and the endogenous GLP-1 mechanism described earlier, extending the same fiber logic BENEO applies to slow-release carbohydrates and prebiotic fibers for weight management [10, 13]. Collagen peptides also crossed into metabolic positioning: ProNutra-Tec presented a plant-based collagen (Vollagen) aimed at the GLP-1 consumer [16], and, as documented in our show recap, compositions such as Rousselot’s Nextida GC were presented for post-meal glucose management and enhanced endogenous GLP-1 secretion, with company-reported clinical data. This blurs the line between companion nutrition and metabolic support, and it widens the ingredient toolkit beyond protein and fiber. For developers weighing these entrants, the underlying processing and format considerations for collagen peptides determine whether they perform in a stick-pack or beverage.

Read more on collagen peptides here:

Collagen as a Nutraceutical Ingredient:
Types, Processing, Formulation, and Supplier Landscape

Format Innovation: Stick-Packs, Sachets, and Melt-in-Mouth

Format was as prominent as ingredients, because the serving-size constraint is a shared problem. Stick-packs and single-serve sachets recurred across launches, including Leanara’s mango stick, as a way to deliver a measured dose in a portable, mix-on-demand, low-volume format suited to a suppressed appetite [8, 13]. Adjacent innovations shown at the event, such as water-free stick formats and melt-in-mouth, directly-dosed powders, point the same direction: reduce the volume and the effort a user has to tolerate. The formulation lesson is consistent with the first half of this article, namely that in this category the delivery format is not packaging around the actives, it is part of whether the product works for the user at all.

Regulatory and Claims Guardrails

The commercial momentum comes with strict claims limits, and the show reflected careful positioning. A dietary supplement cannot claim to diagnose, treat, cure, or prevent disease, so companion products stay within structure-function language (muscle support, satiety, nutrient adequacy) and avoid implying they work like or replace a prescription drug. Substantiated regulatory routes exist for specific ingredients, such as the EFSA-authorised glucomannan weight-management and oat beta-glucan cholesterol claims under their defined conditions of use [6]. The enforcement backdrop is real: the US Food and Drug Administration (FDA) has acted against illegal marketing of compounded GLP-1 products, a reminder that framing a supplement as an equivalent to semaglutide or tirzepatide invites regulatory risk [7]. For formulators and claims teams, the durable takeaway from Vitafoods Europe 2026 is that the winning message is complementary, supporting the user of a medication or a healthy weight-management routine, not competitive with the drug itself.

Frequently Asked Questions

What are GLP-1 support supplements? GLP-1 support supplements, or GLP-1 companion nutrition, are dietary supplements and functional foods formulated for people using GLP-1 receptor agonist drugs such as semaglutide and tirzepatide, or seeking similar support. They target the side effects of sharply reduced food intake: lean-muscle loss, low protein and fiber intake, micronutrient shortfalls, and gastrointestinal discomfort. They are positioned to complement, not replace, the medication.

Which ingredients help preserve muscle during GLP-1 weight loss? Protein is the primary lever, with whey providing rapid amino-acid delivery and casein a sustained release, supported by essential amino acids and leucine. Creatine monohydrate at 5 g per day with resistance training is the adjunct with the strongest clinical support, associated with roughly 1.1 kg more lean mass. HMB is a secondary adjunct with mixed evidence, generally more relevant to older or untrained users.

Can fiber supplements replace GLP-1 medications? No. Fermentable fibers can raise the body’s own GLP-1 through short-chain fatty acid signaling and improve satiety and glucose control, but their standalone weight-loss effect is small, on the order of 0.3 to 0.8 kg versus control, compared with 10 to 20 kg or more for the drugs. Fiber is best positioned for satiety, glycemic support, and tolerability, not as a substitute.

What dosage forms suit GLP-1 users? Because appetite is suppressed, format follows dose. High-dose actives such as protein, fiber, and creatine fit powders, stick-packs, and ready-to-mix shakes, while low-dose actives such as vitamins, B12, and electrolytes suit gummies, effervescents, and capsules. Small, low-volume, easy-to-tolerate formats such as stick-packs and sachets are favored across the category.

Which nutrients are most at risk on GLP-1 therapy? Reduced intake is associated with sub-DRI levels of calcium, iron, magnesium, potassium, and vitamins A, C, D, and E, plus low fiber intake near 14.5 g per day. Observational data indicate more than 22 percent of users develop at least one deficiency within a year, most commonly vitamin D. Risk-based support typically centers on vitamin D, B12, iron, and adequate protein and fiber.

Are health claims for these ingredients approved? Some are. EFSA has authorised a glucomannan weight-management claim (3 g per day in divided doses with water, with a choking warning) and an oat beta-glucan cholesterol claim (3 g per day). In the United States, ingredients can carry substantiated structure-function statements. Disease claims are prohibited for supplements, and marketing a product as equivalent to a GLP-1 drug carries regulatory risk.

Key Takeaways

GLP-1 support supplements target the predictable consequences of drug-driven appetite suppression: lean-mass loss, sub-DRI protein, fiber, and micronutrient intake, and GI side effects.

Protein (whey and casein) and creatine at 5 g per day with resistance training are the best-supported muscle-preservation levers; EAAs, leucine, and HMB are adjuncts on indirect evidence.

Fermentable, viscous fibers aid satiety and can raise endogenous GLP-1 via short-chain fatty acids, but their standalone weight effect is small and GI tolerability is the main formulation limit.

The decisive constraint is nutrient density inside a small, nausea-sensitive serving, which favors stick-packs, sachets, and ready-to-mix formats over large shakes.

No trial has yet tested these supplements alongside a GLP-1 drug, so claims must stay within substantiated structure-function language and avoid disease or drug-equivalence positioning.

Vitafoods Europe 2026 confirmed the category’s direction: muscle-first launches such as HTBA Leanara, fiber and collagen for satiety and metabolic support, and single-serve format innovation.

Sources

1. Anderson, L.J., et al. “Nutritional and supplementation strategies to preserve lean mass during GLP-1 receptor agonist therapy (review).” Obesity Pillars, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12685510/.

2. “Muscle Loss and Supportive Care During GLP-1 Receptor Agonist Therapy: A Review.” Metabolites, 16(6):364, 2026. https://www.mdpi.com/2218-1989/16/6/364.

3. “Nutrient Intake and Micronutrient Status in Adults Using GLP-1 Receptor Agonists.” Nutrients, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12693348/ .

4. Wang, Y., et al. “Dietary fiber, short-chain fatty acids, and the gut-hormone axis: implications for weight management in the GLP-1 era.” Advances in Nutrition, 2026. https://www.sciencedirect.com/science/article/pii/S216183132600061X .

5. “Dietary Fiber in Weight Management: Mechanisms and Clinical Evidence.” Nutrients, 16(4):557, 2024. https://www.mdpi.com/2072-6643/16/4/557.

6. European Commission. “EU Register of nutrition and health claims (glucomannan and oat beta-glucan authorised claims and conditions of use).” EU Food Safety Portal. https://ec.europa.eu/food/food-feed-portal/backend/claims/files/euregister.pdf.

7. US Food and Drug Administration. “FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s.” FDA News. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s.

8. Nutrition Insight. “HTBA targets GLP-1 muscle health and energy with Leanara at Vitafoods Europe.” Nutrition Insight (William Reed). https://www.nutritioninsight.com/news/htba-glp1-muscle-health-energy-vitafoods.html.

9. Nutritional Outlook. “HTBA to launch Leanara at Vitafoods Europe 2026 to support muscle and energy in GLP-1 users.” Nutritional Outlook. https://www.nutritionaloutlook.com/view/htba-to-launch-leanara-at-vitafoods-europe-2026-to-support-muscle-and-energy-in-glp-1-users.

10. Nutrition Insight. “GLP-1 companion products: metabolic health innovations.” Nutrition Insight (William Reed). https://www.nutritioninsight.com/news/glp1-companion-products-metabolic-health-innovations.html.

11. Nutrition Insight. “GLP-1 companion supplements and the nutrition industry.” Nutrition Insight (William Reed). https://www.nutritioninsight.com/news/glp-1-companion-supplements-nutrition-industry.html.

12. Nutrition Insight. “Vitafoods Europe 2026: Arla Foods Ingredients on high-protein concepts.” Nutrition Insight (William Reed). https://www.nutritioninsight.com/news/vitafoods-europe-2026-arla-foods-ingredients.html.

13. Nutrition Insight. “The GLP-1 era: protein and fiber formulation innovation.” Nutrition Insight (William Reed). https://www.nutritioninsight.com/news/glp-1-era-protein-fiber-formulation-innovation.html.

14. NutraIngredients. “Nutrition trends at Vitafoods 2026.” NutraIngredients (William Reed). https://www.nutraingredients.com/Article/2026/05/19/nutrition-trends-at-vitafoods-2026/.

15. FoodBev Media. “Vitafoods Europe 2026: GLP-1, longevity, and women’s health take centre stage.” FoodBev Media. https://www.foodbev.com/news/vitafoods-europe-2026-glp-1-longevity-and-women-s-health-take-centre-stage.

16. Food Ingredients First. “ProNutra-Tec presents Vollagen plant-based collagen for GLP-1 users at Vitafoods.” Food Ingredients First. https://www.foodingredientsfirst.com/news/pronutra-tec-vollagen-plant-based-collagen-glp-1-vitafoods.html.

These statements have not been evaluated by the Food and Drug Administration. This information is provided for dietary supplement industry professionals and is not intended to diagnose, treat, cure, or prevent any disease.

Read more about probiotics as GLP-1 supporting ingredients:

Gut Health Support for GLP-1 Weight-Loss Therapies:
Why the Microbiome Matters – and How Forte80™ Can Help